MX2009007334A - 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity. - Google Patents

6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.

Info

Publication number
MX2009007334A
MX2009007334A MX2009007334A MX2009007334A MX2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A
Authority
MX
Mexico
Prior art keywords
sphingosine
biological activity
phosphate
carboxylic acid
acid amide
Prior art date
Application number
MX2009007334A
Other languages
Spanish (es)
Inventor
Richard L Beard
Haiging Yuan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US88447007P priority Critical
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to PCT/US2008/050695 priority patent/WO2008089015A1/en
Publication of MX2009007334A publication Critical patent/MX2009007334A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1 -phosphate receptor agonist and or antagonist biological activity: Formula (I) and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.
MX2009007334A 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity. MX2009007334A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US88447007P true 2007-01-11 2007-01-11
PCT/US2008/050695 WO2008089015A1 (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Publications (1)

Publication Number Publication Date
MX2009007334A true MX2009007334A (en) 2009-07-15

Family

ID=39399972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007334A MX2009007334A (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.

Country Status (8)

Country Link
EP (1) EP2125723A1 (en)
JP (1) JP2010515750A (en)
KR (1) KR20090101307A (en)
CN (1) CN101668741A (en)
AU (1) AU2008206495A1 (en)
CA (1) CA2674946A1 (en)
MX (1) MX2009007334A (en)
WO (1) WO2008089015A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
AU2009225747A1 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1P3 receptor inhibitors for treating inflammation
SI2326621T1 (en) 2008-07-23 2016-10-28 Arena Pharmaceuticals, Inc. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA(b)INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
RS54970B1 (en) 2008-08-27 2016-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
CN103221391B (en) 2010-01-27 2018-07-06 艾尼纳制药公司 (R) preparation method of -2- (7- (4- cyclopenta -3- (trifluoromethyl) benzyls oxygroup) -1,2,3,4- tetrahydro cyclopentyl diene simultaneouslies [b] indol-3-yl) acetic acid and its salt
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
TWI522361B (en) * 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivatives as s1p modulators
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121394B1 (en) * 1971-01-08 1974-03-22 Anvar
EP0146810A3 (en) 1983-12-05 1987-05-13 Solco Basel AG Process for the preparation of sphingosin derivatives
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA9002794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
HU9900424A2 (en) 1996-01-22 1999-05-28 Fujisawa Pharmaceutical Co., Ltd. Thiazolylbenzofuran derivatives and pharmaceutical compositions containing them
KR100559817B1 (en) 1997-03-12 2006-03-10 다카라 바이오 가부시키가이샤 Sphingosine analogues
KR100561890B1 (en) 1997-09-11 2006-03-16 다카라 바이오 가부시키가이샤 Sphingosine derivatives and medicinal composition
DE19753522A1 (en) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituted indoles, their preparation and their use as pharmaceuticals
KR20010086166A (en) 1999-01-13 2001-09-08 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Functionalized Heterocycles as Chemokine Receptor Modulators
AU6431301A (en) 2000-06-20 2002-01-02 Japan Tobacco Inc Pyrazolopyridine compounds and use thereof as drugs
EP1397130B1 (en) 2001-06-20 2007-07-25 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003211362A1 (en) * 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
JP2009526863A (en) 2006-02-15 2009-07-23 アラーガン、インコーポレイテッドAllergan,Incorporated Sphingosine-1-phosphate (S1P) receptor antagonists Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds having aryl or heteroaryl groups with biological activity

Also Published As

Publication number Publication date
CN101668741A (en) 2010-03-10
JP2010515750A (en) 2010-05-13
KR20090101307A (en) 2009-09-24
WO2008089015A1 (en) 2008-07-24
EP2125723A1 (en) 2009-12-02
CA2674946A1 (en) 2008-07-24
AU2008206495A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
RU2495044C2 (en) Protein tyrosine kinase activity inhibitors
CY1121601T1 (en) DIAMIDE COMPOUNDS THAT HAVE MUSCARINE RECEPTOR COMPETITIVE ACTIVITY AND STRUCTURAL BETA 2 ADRENERGIC RECEPTOR
CR20140215A (en) Cyclopenta (d) pyrimidines as akt protein kinase inhibitors
BR112015007182A2 (en) gdf-8 inhibitors
RU2470918C2 (en) NOVEL INDOLE DERIVATIVES HAVING IκB KINASE β INHIBITING ACTIVITY
NI201200016A (en) Pyridine and pyrazine derivatives as protein kinase modulators
IL219373D0 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
IL209061D0 (en) Triazine compounds as p13 kinase and mtor inhibitors
BR112014003237A2 (en) indazole compounds, compositions and methods of use
BR112012030820A2 (en) "aminopyrimidine derivatives as lrrk2 modulators"
HK1129678A1 (en) Processes and intermediates for the preparation of n4-phenyl-quinazoline-4- amine derivatives
HRP20130968T1 (en) Adamantyl diamide derivatives and uses of same
MX336189B (en) Anti parasitic dihydroazole compounds and compositions comprising same.
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
NO20083514L (en) Heterobicyclic sulfonamide derivatives for the treatment of diabetes
GT200700106A (en) New herbicides
NZ598985A (en) Bruton's tyrosine kinase inhibitors
UA92490C2 (en) Imidazoquinolines as lipid kinase inhibitors
CY1118135T1 (en) 2- (phenyl or pyrid-3-yl) aminopyrimidine as a kinase buffer lrrk2 for the treatment of parkinson's disease
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EA201200373A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINAZ INHIBITORS
TW200619218A (en) Pyrimidines as PLK inhibitors
WO2007133653A3 (en) Methods for treating blood disorders
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal